Compare MGM Resorts International (MGM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs ResMed Inc. — how do they compare? MGM Resorts International trades at $43.76 (market cap $11.10B), while ResMed Inc. trades at $223.5 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 2.9× MGM Resorts International's market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| MGM | RMD | |
|---|---|---|
Market Cap | $11.10B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $293.73 |
52-Week Low | $30.72 | $182.82 |
Enterprise Value | $38.40B | $31.97B |
Dividend Yield | 0.03% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $43.36, down 2.5% with bearish technical signals despite mixed earnings performance. The company reported record Q2 2026 revenue of $17.54B but missed EPS estimates, while analyst consensus remains divided with a $51.14 price target. Recent news highlights ongoing acquisition investigations and BetMGM's expansion in Canadian markets.
MGM faces near-term pressure from earnings volatility and acquisition uncertainty, but maintains strong revenue growth and digital expansion. Key risks include regulatory scrutiny and competitive pressures, while institutional sentiment leans neutral with balanced buy/hold ratings suggesting cautious optimism for recovery.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
